- Home
- IMVT vs GLOB Comparison
IMVT vs GLOB Comparison
Compare IMVT & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMVT | GLOB |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.7B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMVT | GLOB |
|---|---|---|
| Price | $26.19 | $67.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $27.75 | ★ $95.71 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.19 |
| Revenue | N/A | ★ $2,484,891,000.00 |
| Revenue This Year | N/A | $3.37 |
| Revenue Next Year | N/A | $1.84 |
| P/E Ratio | ★ N/A | $30.76 |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $12.72 | $54.36 |
| 52 Week High | $27.69 | $228.98 |
Technical Indicators
Market Signals| Indicator | IMVT | GLOB |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 54.07 |
| Support Level | $26.35 | $66.10 |
| Resistance Level | $27.64 | $68.62 |
| Average True Range (ATR) | 1.39 | 2.51 |
| MACD | 0.06 | -0.28 |
| Stochastic Oscillator | 71.64 | 29.97 |
Price Performance
Historical ComparisonAbout IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.